Swiss National Bank Buys 1,318,900 Shares of Merck & Co., Inc. (NYSE:MRK)
Swiss National Bank Buys 1,318,900 Shares of Merck & Co., Inc. (NYSE:MRK)
Swiss National Bank raised its stake in shares of Merck & Co., Inc. (NYSE:MRK – Get Rating) by 13.7% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 10,940,532 shares of the company's stock after acquiring an additional 1,318,900 shares during the period. Swiss National Bank owned approximately 0.43% of Merck & Co., Inc. worth $897,671,000 as of its most recent SEC filing.
据瑞士央行最近提交给美国证券交易委员会的文件显示，该行今年第一季度将默克公司(Merck&Co.，Inc.)股票持股比例提高了13.7%。该公司在此期间增持了1,318,900股后，持有该公司10,940,532股股票。截至最近提交的美国证券交易委员会申请文件，瑞士国家银行持有默克公司约0.43%的股份，价值897,671,000美元。
Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Bromfield Sneider Wealth Advisors purchased a new stake in shares of Merck & Co., Inc. during the 1st quarter valued at about $79,000. Hikari Power Ltd increased its position in shares of Merck & Co., Inc. by 5.0% during the 1st quarter. Hikari Power Ltd now owns 23,630 shares of the company's stock valued at $1,939,000 after purchasing an additional 1,130 shares during the last quarter. ACG Wealth increased its position in shares of Merck & Co., Inc. by 5.6% during the 1st quarter. ACG Wealth now owns 13,523 shares of the company's stock valued at $1,110,000 after purchasing an additional 722 shares during the last quarter. Mascoma Wealth Management LLC increased its position in shares of Merck & Co., Inc. by 36.4% during the 1st quarter. Mascoma Wealth Management LLC now owns 926 shares of the company's stock valued at $76,000 after purchasing an additional 247 shares during the last quarter. Finally, WealthBridge Investment Counsel Inc. increased its position in shares of Merck & Co., Inc. by 4.1% during the 1st quarter. WealthBridge Investment Counsel Inc. now owns 87,820 shares of the company's stock valued at $7,206,000 after purchasing an additional 3,475 shares during the last quarter. Institutional investors own 72.88% of the company's stock.
其他几家对冲基金和其他机构投资者也买卖了该股的股票。Bromfield Sneider Wealth Advisors在第一季度购买了默克公司(Merck&Co.，Inc.)新股，价值约7.9万美元。Hikari Power Ltd在第一季度增持了默克公司股票5.0%的头寸。Hikari Power Ltd现在拥有该公司23,630股股票，价值1,939,000美元，此前该公司在上个季度又购买了1,130股股票。ACG Wealth在第一季度增持了默克公司股票5.6%。ACG Wealth在上个季度又购买了722股，现在拥有13,523股该公司股票，价值111万美元。Mascoma Wealth Management LLC在第一季度将其在默克公司股票的持仓增加了36.4%。Mascoma Wealth Management LLC在上个季度额外购买了247股后，现在拥有926股该公司股票，价值7.6万美元。最后，WealthBridge Investment Counsel Inc.在第一季度将其持有的默克公司股票头寸增加了4.1%。WealthBridge Investment Counsel Inc.现在持有87,820股该公司股票，价值7,206,000美元，该公司在上个季度又购买了3,475股。机构投资者持有该公司72.88%的股票。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
Several equities research analysts have recently commented on the stock. Mizuho assumed coverage on shares of Merck & Co., Inc. in a research report on Friday, June 24th. They set a "buy" rating and a $100.00 price target for the company. Cowen increased their target price on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the stock a "market perform" rating in a report on Monday, June 27th. UBS Group increased their target price on shares of Merck & Co., Inc. from $76.00 to $98.00 and gave the stock a "neutral" rating in a report on Monday, July 18th. SVB Leerink reissued an "outperform" rating and issued a $102.00 target price on shares of Merck & Co., Inc. in a report on Monday, June 6th. Finally, Daiwa Capital Markets raised shares of Merck & Co., Inc. from a "neutral" rating to a "buy" rating and increased their target price for the stock from $89.00 to $102.00 in a report on Wednesday, July 6th. Eight equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $97.44.
几位股票研究分析师最近对该股发表了评论。瑞穗在6月24日星期五的一份研究报告中对默克公司的股票进行了报道。他们为该公司设定了“买入”评级和100.00美元的目标价。考恩将默克公司股票的目标价从95美元上调至102.00美元，并在6月27日星期一的一份报告中给出了该股的“市场表现”评级。瑞银集团在7月18日周一的一份报告中将默克公司股票的目标价从76.00美元上调至98.00美元，并给予该股“中性”评级。SVB Leerink在6月6日周一的一份报告中重新发布了对默克公司的评级，并将默克公司的股票目标价定为102.00美元。最后，在7月6日周三的一份报告中，大和资本市场将默克公司的股票评级从中性上调至买入，并将该股的目标价从89美元上调至102.00美元。8名股票研究分析师对该股的评级为持有，9名分析师给予该公司买入评级，2名分析师给予该公司强烈的买入评级。根据MarketBeat的数据，该股目前的平均评级为“适度买入”，共识目标价为97.44美元。
Merck & Co., Inc. Stock Up 0.7 %
默克公司股价上涨0.7%
Merck & Co., Inc. (NYSE:MRK – Get Rating) last posted its earnings results on Thursday, July 28th. The company reported $1.87 EPS for the quarter, beating analysts' consensus estimates of $1.69 by $0.18. The firm had revenue of $14.59 billion during the quarter, compared to the consensus estimate of $13.85 billion. Merck & Co., Inc. had a return on equity of 50.02% and a net margin of 29.00%. The company's quarterly revenue was up 28.0% compared to the same quarter last year. During the same period in the prior year, the company earned $1.31 EPS. As a group, equities analysts predict that Merck & Co., Inc. will post 7.31 EPS for the current fiscal year.
默克公司(纽约证券交易所代码：MRK-GET评级)最近一次公布收益报告是在7月28日星期四。该公司公布本季度每股收益为1.87美元，比分析师普遍预期的1.69美元高出0.18美元。该公司本季度营收为145.9亿美元，而市场普遍预期为138.5亿美元。默克公司的股本回报率为50.02%，净利润率为29.00%。与去年同期相比，该公司的季度收入增长了28.0%。去年同期，该公司每股收益为1.31美元。股票分析师预计，作为一个整体，默克公司本财年每股收益将达到7.31欧元。
Merck & Co., Inc. Dividend Announcement
默克公司宣布分红
The company also recently announced a quarterly dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 15th will be given a dividend of $0.69 per share. The ex-dividend date is Wednesday, September 14th. This represents a $2.76 dividend on an annualized basis and a dividend yield of 3.16%. Merck & Co., Inc.'s dividend payout ratio is currently 42.27%.
该公司最近还宣布了季度股息，将于10月7日(星期五)支付。9月15日(星期四)登记在册的股东将获得每股0.69美元的股息。除息日为9月14日星期三。这意味着年化股息为2.76美元，股息收益率为3.16%。默克公司目前的股息支付率为42.27%。
Merck & Co., Inc. Profile
默克公司简介
(Get Rating)
(获取评级)
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.
默克公司是一家全球性的医疗保健公司。它通过两个部门运作，制药和动物健康。制药部门提供肿瘤学、医院急性护理、免疫学、神经科学、病毒学、心血管和糖尿病等领域的人类健康药物产品，以及疫苗产品，如预防性儿科、青少年和成人疫苗。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Merck & Co., Inc. (MRK)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- 免费获取StockNews.com关于默克公司的研究报告(MRK)
- MarketBeat：回顾中的一周8/1-8/5
- 如何利用高贝塔系数股票最大化你的投资利润
- 克罗诺斯集团(Cronos Group Inc.)营收上升，是时候收购了吗？
- 苹果为何可能在年底创下历史新高
- Beyond Meat不是没有希望，而且它很便宜
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Get Rating).
想看看还有哪些对冲基金持有MRK吗？访问HoldingsChannel.com获取默克公司(NYSE：MRK-GET Rating)的最新13F文件和内幕交易信息。
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
每天收到默克公司的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对默克公司和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。